What is the 13F Pro Quality Score for ACLX?

13F Pro ranks Arcellx, Inc. (ACLX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ACLX's current score at https://13fpro.ai/research/ACLX (free sign-up required for the full ranking).

Which hedge funds own the most ACLX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ACLX include GILEAD SCIENCES,, Paradigm Biocapital Advisors, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ACLX as soon as new 13F filings post.

Where does 13F Pro source ACLX data?

All Arcellx, Inc. fundamentals and ownership data come directly from SEC EDGAR. Arcellx, Inc. files with the SEC under CIK 1786205. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ACLX in?

Arcellx, Inc. (ACLX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ACLX research updated on 13F Pro?

ACLX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Arcellx, Inc.(ACLX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1786205 ACLX stock profile & AI dashboard →

13F Pro Quality Score

6.7/100

Rank #2,840 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

4.0/100

Profitability

3.8/100

Balance Sheet

6.8/100

Earnings Quality

30.0/100

Free Cash Flow

4.6/100

Institutional Flow

5.6/100

Revenue Scale

10.3/100

Dilution Risk

1.5/100

ACLX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Arcellx, Inc. (ACLX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ACLX at 6.7/100 on a 32-signal composite quality model, placing it at rank #2,840 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (3.8) and revenue growth (4.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q4 2025), Arcellx, Inc. reports quarterly revenue of $1.7M, net income of $-58.1M, free cash flow of $-58.9M. Top institutional holders of ACLX by reported 13-F value include GILEAD SCIENCES,, Paradigm Biocapital Advisors, BlackRock,, based on the most recent SEC filings. ACLX trades on the Nasdaq exchange and files with the SEC under CIK 1786205. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ACLX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Arcellx, Inc. directly from SEC EDGAR. Arcellx, Inc.'s 13F Pro composite quality score has ranged between 7 and 64 since 2024, currently 6.7 — a declining long-term trajectory across 44 quarterly and live scoring snapshots.

✦

Fun facts about Arcellx, Inc.

Quirks, history, and lore behind ACLX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · focused on cell therapy · listed on Nasdaq · headquartered in Maryland.
2
The Numbers
A relatively small-cap biotech with minimal product revenue — the company runs largely on partnership funding and equity raises while its therapies advance through trials.
3
The History
Founded in the 2010s, it was built around a novel approach to engineering T-cell therapies and went public on Nasdaq in 2023.
4
The Secret
Its platform uses a proprietary non-viral vector technology to engineer cells, aiming to sidestep the manufacturing headaches that plague most CAR-T rivals.
5
The Lore
Its lead program targets multiple myeloma — one of the most competitive battlegrounds in oncology — and has drawn a significant collaboration with GSK to develop it.
6
The Giveaway
The ticker spells out the mission: this Gaithersburg cell therapy upstart is engineering a new class of CART-ddBCMA treatments, and its name sounds like it was coined in a sci-fi writers' room.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q4 2025

$1.7M

Net Income

Q4 2025

$-58.1M

Free Cash Flow

Q4 2025

$-58.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-79.8% YoY

$22.3MFY 2025

FY22 —FY23 $110.3MFY25 $22.3M

Net Income

-223.9% YoY

$-228.9MFY 2025

FY22 $-188.7MFY23 $-70.7MFY25 $-228.9M

Operating Income

-181.6% YoY

$-253.1MFY 2025

FY22 $-191.3MFY23 $-89.9MFY25 $-253.1M

EPS (Diluted)

-176.9% YoY

$-4.07FY 2025

FY22 $-5.19FY23 $-1.47FY25 $-4.07

Total Assets

-26.8% YoY

$604.0MFY 2025

FY22 $313.8MFY23 $825.1MFY25 $604.0M

Op. Cash Flow

-201.3% YoY

$-210.3MFY 2025

FY22 $-99.3MFY23 $207.6MFY25 $-210.3M

Metric	FY 2025	FY 2023	FY 2022
Revenue	$22.3M -79.8%	$110.3M	—
Net Income	$-228.9M -223.9%	$-70.7M +62.5%	$-188.7M
Operating Income	$-253.1M -181.6%	$-89.9M +53.0%	$-191.3M
EPS (Diluted)	$-4.07 -176.9%	$-1.47 +71.7%	$-5.19
Total Assets	$604.0M -26.8%	$825.1M +162.9%	$313.8M
Operating Cash Flow	$-210.3M -201.3%	$207.6M +309.0%	$-99.3M

AI Insight: ACLX Financial Trends

Revenue collapsed 95% from Q1 2024 to Q4 2025 while quarterly cash burn deepened to $58M, eroding equity from $497M to $402M.

• Revenue fell sharply from $39M in Q1 2024 to just $2M in Q4 2025, an 95% decline over eight quarters.

• Operating losses widened from -$16M in Q1 2024 to -$64M in Q4 2025, reflecting accelerating R&D spend with no offsetting revenue.

• Equity eroded from $497M in Q1 2024 to $402M in Q4 2025 as cumulative net losses absorbed roughly $95M of book value.

⚠ Operating cash burn hit -$63M in Q1 2025; at Q4 2025's -$58M run rate, the $402M equity base faces continued drawdown.

⚠ No debt reported across all periods — monitor whether Arcellx raises dilutive equity or takes on debt to fund ongoing burn.

⚠ Q3 2025 equity rose to $441M before falling to $402M in Q4 2025, suggesting a capital raise occurred — watch for follow-on offerings.

Get alerted when ACLX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Arcellx, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ACLX

GILEAD SCIENCES, INC.
$771.7M6,720,803 sh
Paradigm Biocapital Advisors LP
$663.0M5,774,016 sh
BlackRock, Inc.
$453.0M3,945,238 sh
NEA Management Company, LLC
$349.7M3,045,262 sh
Pentwater Capital Management LP
$329.5M2,870,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$278.5M2,425,218 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$278.4M2,424,818 sh
SR ONE CAPITAL MANAGEMENT, LP
$269.4M2,346,630 sh
FIL Ltd
$268.6M2,339,192 sh
HBK INVESTMENTS L P
$261.6M2,278,517 sh

Fund	Value	Shares
GILEAD SCIENCES, INC.	$771.7M	6,720,803
Paradigm Biocapital Advisors LP	$663.0M	5,774,016
BlackRock, Inc.	$453.0M	3,945,238
NEA Management Company, LLC	$349.7M	3,045,262
Pentwater Capital Management LP	$329.5M	2,870,000
VANGUARD CAPITAL MANAGEMENT LLC	$278.5M	2,425,218
VANGUARD PORTFOLIO MANAGEMENT LLC	$278.4M	2,424,818
SR ONE CAPITAL MANAGEMENT, LP	$269.4M	2,346,630
FIL Ltd	$268.6M	2,339,192
HBK INVESTMENTS L P	$261.6M	2,278,517

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ACLX on your watchlist

Track score changes the day Arcellx, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ACLX a good stock to buy?

13F Pro's AI-powered analysis of Arcellx, Inc. (ACLX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ACLX are available on the ACLX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ACLX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ACLX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Arcellx, Inc.'s investment landscape.